Advanced Biomed Inc

Advanced Biomed Inc (ADVB) Stock Analysis

$5.140

-0.020 (-0.39%)At close

Loading chart…
High
5.550
Open
5.260
VWAP
5.28
Volume
13.72K
Mkt Cap
—
Low
5.140
Amount
72.40K
EV/EBITDA, TTM
0.00

Advanced Biomed Inc. is a holding company that operates, through its subsidiary, Advanced Biomed Inc. (Taiwan). The Company is engaged in the provision of assay products and services for cancer patients. These services include early screening and detection, diagnosis and staging, and treatment of cancer through the detection of circulating tumor cells and related tumor markers. It has developed a microfluidic technology platform to integrate research and development, design, and manufacture of biochips and microfluidic chips. The platform combines its patented chip technology and will enable localized operations of a variety of microfluidic chips, biosensors made by semiconductor fabrication technology, and integrated application patented technology. The Company offers devices, such as A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre-Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip.

AI analysis of Advanced Biomed Inc (ADVB)

Sell

Advanced Biomed Inc. is not a good buy right now due to its extremely low RSI of 19.002, indicating oversold conditions, and a significant recent decline of 21.10% over the last five days. The stock is currently trading at $5.31, which is far below its recent highs of $20.87, suggesting a volatile and risky investment. The company also reported a negative net income of -488,942 USD in Q3 2026, which raises concerns about its financial stability.

Valuation Metrics

The current forward P/E ratio for Advanced Biomed Inc (ADVB) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
Overvalued
0.00
Undervalued
0.00

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued
0.00
Undervalued
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
Overvalued
0.00
Undervalued
0.00

Alphio AI Price Scenarios for ADVB

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ADVB

$0.72

Scenario price

B

Base

Base · 50%ADVB

$0.61

Scenario price

B

Bear

Bear · 25%ADVB

$0.56

Scenario price

Events Timeline

2026-07-30 (ET)

10:00:00

Advanced Biomed Inc Trading Halted Due to Volatility

2026-07-27 (ET)

10:00:00

Advanced Biomed Inc Trading Halted Due to Volatility

2026-07-24 (ET)

11:00:00

Advanced Biomed Inc Trading Halted Due to Volatility

2026-07-23 (ET)

10:30:00

Advanced Biomed Inc Trading Halted Due to Volatility

2026-07-22 (ET)

10:00:00

Advanced Biomed Inc Trading Halted Due to Volatility

News

ADVB FAQ — answered by Alphio AI

Advanced Biomed Inc. is a holding company that operates, through its subsidiary, Advanced Biomed Inc. (Taiwan). The Company is engaged in the provision of assay products and services for cancer patients. These services include early screening and detection, diagnosis and staging, and treatment of cancer through the detection of circulating tumor cells and related tumor markers. It has developed a microfluidic technology platform to integrate research and development, design, and manufacture of biochips and microfluidic chips. The platform combines its patented chip technology and will enable localized operations of a variety of microfluidic chips, biosensors made by semiconductor fabrication technology, and integrated application patented technology. The Company offers devices, such as A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre-Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip. It operates in the Healthcare sector.

Advanced Biomed Inc. is not a good buy right now due to its extremely low RSI of 19.002, indicating oversold conditions, and a significant recent decline of 21.10% over the last five days. The stock is currently trading at $5.31, which is far below its recent highs of $20.87, suggesting a volatile and risky investment. The company also reported a negative net income of -488,942 USD in Q3 2026, which raises concerns about its financial stability.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading